

ACTION: Notice.

SUMMARY: The Commission hereby gives notice of the scheduling of expedited reviews pursuant to the Tariff Act of 1930 (“the Act”) to determine whether revocation of the antidumping duty and countervailing duty orders on hardwood plywood from China would be likely to lead to continuation or recurrence of material injury within a reasonably foreseeable time.

DATES: March 6, 2023.

FOR FURTHER INFORMATION CONTACT: (Stamen Borisson (202) 205–3125), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission’s TDD terminal on 202–205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (<https://www.usitc.gov>). The public record for this proceeding may be viewed on the Commission’s electronic docket (EDIS) at <https://edis.usitc.gov>.

SUPPLEMENTARY INFORMATION:

Background.—On March 6, 2023, the Commission determined that the domestic interested party group response to its notice of institution (87 FR 73792, December 1, 2022) of the subject five-year reviews was adequate and that the respondent interested party group response was inadequate. The Commission did not find any other circumstances that would warrant conducting full reviews.¹ Accordingly, the Commission determined that it would conduct expedited reviews pursuant to section 751(c)(3) of the Tariff Act of 1930 (19 U.S.C. 1675(c)(3)).²

For further information concerning the conduct of these reviews and rules of general application, consult the Commission’s Rules of Practice and Procedure, part 201, subparts A and B (19 CFR part 201), and part 207, subparts A, D, E, and F (19 CFR part 207).

Staff report.—A staff report containing information concerning the

subject matter of the reviews has been placed in the nonpublic record, and will be made available to persons on the Administrative Protective Order service list for these reviews on April 19, 2023. A public version will be issued thereafter, pursuant to § 207.62(d)(4) of the Commission’s rules.

Written submissions.—As provided in § 207.62(d) of the Commission’s rules, interested parties that are parties to the reviews and that have provided individually adequate responses to the notice of institution,³ and any party other than an interested party to the reviews may file written comments with the Secretary on what determination the Commission should reach in the reviews. Comments are due on or before April 27, 2023 and may not contain new factual information. Any person that is neither a party to the five-year reviews nor an interested party may submit a brief written statement (which shall not contain any new factual information) pertinent to the reviews by April 27, 2023. However, should the Department of Commerce (“Commerce”) extend the time limit for its completion of the final results of its reviews, the deadline for comments (which may not contain new factual information) on Commerce’s final results is three business days after the issuance of Commerce’s results. If comments contain business proprietary information (BPI), they must conform with the requirements of §§ 201.6, 207.3, and 207.7 of the Commission’s rules. The Commission’s *Handbook on Filing Procedures*, available on the Commission’s website at https://www.usitc.gov/documents/handbook_on_filing_procedures.pdf, elaborates upon the Commission’s procedures with respect to filings.

In accordance with §§ 201.16(c) and 207.3 of the rules, each document filed by a party to the reviews must be served on all other parties to the reviews (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

³ The Commission has found the domestic interested party responses submitted on behalf of the Coalition for Fair Trade in Hardwood Plywood and its individual members, Columbia Forest Products, Commonwealth Plywood Co., Ltd., Manthei Wood Products, States Industries LLC, and Timber Products Company, and respondent interested party responses submitted on behalf of Canusa Wood Products Limited, Hardwoods Specialty Products USLP, Holland Southwest International, Inc., McCorry & Company Limited, Medallion Forest Products, Northwest Hardwoods, Inc., Richmond International Forest Products, LLC, and Taraca Pacific, Inc., to be individually adequate. Comments from other interested parties will not be accepted (*see* 19 CFR 207.62(d)(2)).

Determination.—The Commission has determined these reviews are extraordinarily complicated and therefore has determined to exercise its authority to extend the review period by up to 90 days pursuant to 19 U.S.C. 1675(c)(5)(B).

Authority: These reviews are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to § 207.62 of the Commission’s rules.

By order of the Commission.

Issued: March 30, 2023.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2023–06971 Filed 4–3–23; 8:45 am]

BILLING CODE 7020–02–P

JOINT BOARD FOR THE ENROLLMENT OF ACTUARIES

Meeting of the Advisory Committee; Meeting

AGENCY: Joint Board for the Enrollment of Actuaries.

ACTION: Notice of Federal Advisory Committee meeting.

SUMMARY: The Joint Board for the Enrollment of Actuaries gives notice of a closed teleconference meeting of the Advisory Committee on Actuarial Examinations.

DATES: The meeting will be held on April 21, 2023, from 10:00 a.m. to 5:00 p.m. (EDT).

FOR FURTHER INFORMATION CONTACT: Elizabeth Van Osten, Designated Federal Officer, Advisory Committee on Actuarial Examinations, at (202) 317–3648 or elizabeth.j.vanosten@irs.gov.

SUPPLEMENTARY INFORMATION: Notice is hereby given that the Advisory Committee on Actuarial Examinations will hold a teleconference meeting on April 21, 2023, from 10:00 a.m. to 5:00 p.m. (EDT). The meeting will be closed to the public.

The purpose of the meeting is to discuss topics and questions that may be recommended for inclusion on future Joint Board examinations in actuarial mathematics, pension law and methodology referred to in 29 U.S.C. 1242(a)(1)(B).

A determination has been made as required by section 10(d) of the Federal Advisory Committee Act, 5 U.S.C. 1009, that the subject of the meeting falls within the exception to the open meeting requirement set forth in 5 U.S.C. 552b(c)(9)(B), and that the public interest requires that such meeting be closed to public participation.

¹ A record of the Commissioners’ votes, the Commission’s statement on adequacy, and any individual Commissioner’s statements will be available from the Office of the Secretary and at the Commission’s website.

² Chairman David S. Johanson and Commissioner Amy A. Karpel found that the respondent interested party group response was adequate and voted to conduct full reviews.

Dated: March 30, 2023.
Thomas V. Curtin, Jr.,
*Executive Director, Joint Board for the
 Enrollment of Actuaries.*
 [FR Doc. 2023-06977 Filed 4-3-23; 8:45 am]
BILLING CODE 4830-01-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1160]

**Importer of Controlled Substances
 Application: Sharp Clinical Services,
 LLC**

AGENCY: Drug Enforcement
 Administration, Justice.

ACTION: Notice of application.

SUMMARY: Sharp Clinical Services, LLC
 has applied to be registered as an
 importer of basic class(es) of controlled
 substance(s). Refer to **SUPPLEMENTARY
 INFORMATION** listed below for further
 drug information.

DATES: Registered bulk manufacturers of
 the affected basic class(es), and
 applicants therefore, may submit
 electronic comments on or objections to
 the issuance of the proposed registration
 on or before May 4, 2023. Such persons
 may also file a written request for a
 hearing on the application on or before
 May 4, 2023.

ADDRESSES: The Drug Enforcement
 Administration requires that all
 comments be submitted electronically
 through the Federal eRulemaking Portal,
 which provides the ability to type short
 comments directly into the comment
 field on the web page or attach a file for
 lengthier comments. Please go to
<https://www.regulations.gov> and follow
 the online instructions at that site for
 submitting comments. Upon submission
 of your comment, you will receive a
 Comment Tracking Number. Please be
 aware that submitted comments are not
 instantaneously available for public
 view on <https://www.regulations.gov>. If
 you have received a Comment Tracking
 Number, your comment has been
 successfully submitted and there is no
 need to resubmit the same comment. All
 requests for a hearing must be sent to:
 (1) Drug Enforcement Administration,
 Attn: Hearing Clerk/OALJ, 8701
 Morrisette Drive, Springfield, Virginia
 22152; and (2) Drug Enforcement
 Administration, Attn: DEA Federal
 Register Representative/DPW, 8701
 Morrisette Drive, Springfield, Virginia
 22152. All requests for a hearing should
 also be sent to: Drug Enforcement
 Administration, Attn: Administrator,

8701 Morrisette Drive, Springfield,
 Virginia 22152.

SUPPLEMENTARY INFORMATION: In
 accordance with 21 CFR 1301.34(a), this
 is notice that on February 8, 2023, Sharp
 Clinical Services, LLC, 2400 Baglyos
 Circle, Bethlehem, Pennsylvania 18020-
 8024, applied to be registered as an
 importer of the following basic class(es)
 of controlled substance(s):

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid	2010	I
3,4-Methylenedioxymethamphetamine.	7405	I
5-Methoxy-N-N-dimethyltryptamine.	7431	I

The company plans to import the
 listed controlled substances for
 distribution and clinical trials. No other
 activities for these drug codes are
 authorized for this registration.

Approval of permit applications will
 occur only when the registrant's
 business activity is consistent with what
 is authorized under 21 U.S.C. 952(a)(2).
 Authorization will not extend to the
 import of Food and Drug
 Administration-approved or non-
 approved finished dosage forms for
 commercial sale.

Matthew Strait,
Deputy Assistant Administrator.
 [FR Doc. 2023-06948 Filed 4-3-23; 8:45 am]
BILLING CODE 4410-09-P

comments be submitted electronically
 through the Federal eRulemaking Portal,
 which provides the ability to type short
 comments directly into the comment
 field on the web page or attach a file for
 lengthier comments. Please go to
<https://www.regulations.gov> and follow
 the online instructions at that site for
 submitting comments. Upon submission
 of your comment, you will receive a
 Comment Tracking Number. Please be
 aware that submitted comments are not
 instantaneously available for public
 view on <https://www.regulations.gov>. If
 you have received a Comment Tracking
 Number, your comment has been
 successfully submitted and there is no
 need to resubmit the same comment. All
 requests for a hearing must be sent to:
 (1) Drug Enforcement Administration,
 Attn: Hearing Clerk/OALJ, 8701
 Morrisette Drive, Springfield, Virginia
 22152; and (2) Drug Enforcement
 Administration, Attn: DEA Federal
 Register Representative/DPW, 8701
 Morrisette Drive, Springfield, Virginia
 22152. All requests for a hearing should
 also be sent to: Drug Enforcement
 Administration, Attn: Administrator,
 8701 Morrisette Drive, Springfield,
 Virginia 22152.

SUPPLEMENTARY INFORMATION: In
 accordance with 21 CFR 1301.34(a), this
 is notice that on January 28, 2023,
 SpecGX LLC, 3600 North 2nd Street,
 Saint Louis, Missouri 63147, applied to
 be registered as an importer of the
 following basic class(es) of controlled
 substance(s):

Controlled substance	Drug code	Schedule
Marihuana	7360	I
Phenylacetone	8501	II
Coca Leaves	9040	II
Thebaine	9333	II
Opium, Raw	9600	II
Poppy Straw Con- centrate.	9670	II
Tapentadol	9780	II

The company plans to import the
 listed controlled substances for bulk
 manufacture into Active Pharmaceutical
 Ingredients (API) for distribution to its
 customers. In reference to Tapentadol
 (9780) and Thebaine (9333), the
 company plans to import intermediate
 forms of these controlled substances for
 further manufacturing prior to
 distribution to its customers. In
 reference to drug code 7360
 (Marihuana), the company plans to
 import synthetic cannabinol. No other
 activity for this drug is authorized for
 this registration. Placement of these
 codes onto the company's registration
 does not translate into automatic
 approval of subsequent permit

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1177]

**Importer of Controlled Substances
 Application: SpecGX LLC**

AGENCY: Drug Enforcement
 Administration, Justice.

ACTION: Notice of application.

SUMMARY: SpecGX, LLC has applied to
 be registered as an importer of basic
 class(es) of controlled substance(s).
 Refer to Supplemental Information
 listed below for further drug
 information.

DATES: Registered bulk manufacturers of
 the affected basic class(es), and
 applicants therefore, may submit
 electronic comments on or objections to
 the issuance of the proposed registration
 on or before May 4, 2023. Such persons
 may also file a written request for a
 hearing on the application on or before
 May 4, 2023.

ADDRESSES: The Drug Enforcement
 Administration (DEA) requires that all